NO20091247L - terapeutiske pyrazolyl tienopyridiner - Google Patents

terapeutiske pyrazolyl tienopyridiner

Info

Publication number
NO20091247L
NO20091247L NO20091247A NO20091247A NO20091247L NO 20091247 L NO20091247 L NO 20091247L NO 20091247 A NO20091247 A NO 20091247A NO 20091247 A NO20091247 A NO 20091247A NO 20091247 L NO20091247 L NO 20091247L
Authority
NO
Norway
Prior art keywords
therapeutic
thienopyridines
pyrazolyl
compounds
formula
Prior art date
Application number
NO20091247A
Other languages
English (en)
Inventor
Stephen Douglas Barrett
Huifen Chen
Mark Laurence Boys
James B Kramer
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20091247L publication Critical patent/NO20091247L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det beskrives forbindelser av formel 1, og farmasøytisk akseptable er derav, hvor R1,R2, R2, R4, R5, R6 og R7 har de betydninger som er gitt her i beskrivelsen, og farmasøytisk akseptable salter derav, som er nyttige som terapeutiske midler i behandlingen av TGFß, samt sammensetninger omfattende en eller flere forbindelser av formel I.
NO20091247A 2006-10-16 2009-03-25 terapeutiske pyrazolyl tienopyridiner NO20091247L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85198206P 2006-10-16 2006-10-16
PCT/IB2007/002994 WO2008047198A1 (en) 2006-10-16 2007-10-04 Therapeutic pyrazolyl thienopyridines

Publications (1)

Publication Number Publication Date
NO20091247L true NO20091247L (no) 2009-04-23

Family

ID=38962671

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091247A NO20091247L (no) 2006-10-16 2009-03-25 terapeutiske pyrazolyl tienopyridiner

Country Status (16)

Country Link
US (5) US7964612B2 (no)
EP (2) EP2074128B1 (no)
JP (1) JP5443988B2 (no)
KR (1) KR20090066297A (no)
CN (1) CN101528752A (no)
AR (1) AR063318A1 (no)
AU (1) AU2007311560B2 (no)
CA (1) CA2666603C (no)
CL (1) CL2007002916A1 (no)
ES (2) ES2559521T3 (no)
IL (1) IL197750A0 (no)
MX (1) MX2009003157A (no)
NO (1) NO20091247L (no)
TW (1) TW200825094A (no)
UY (1) UY30641A1 (no)
WO (1) WO2008047198A1 (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090066297A (ko) 2006-10-16 2009-06-23 화이자 프로덕츠 인크. 치료용 피라졸릴 티에노피리딘
WO2009089324A1 (en) 2008-01-08 2009-07-16 Yale University Compositions and methods for promoting patency of vascular grafts
HRP20140680T1 (hr) 2008-12-29 2014-10-10 Sanofi Derivati 2-piridin-2-ilpirazol-3(2h)-ona, njihovo dobivanje i njihova upotreba u terapiji kao aktivatora hif
FR2949468B1 (fr) * 2009-08-28 2011-09-30 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique
FR2940652B1 (fr) * 2008-12-29 2011-02-11 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique
MX2011007061A (es) * 2008-12-29 2011-12-16 Sanofi Sa Derivados de 2 piridin- 2-il-pirazol-3 (2h)-ona, su preparacion y aplicacion terapeutica.
CA2758071C (en) * 2009-04-06 2018-01-09 Agios Pharmaceuticals, Inc. Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
SG10201403696UA (en) 2009-06-29 2014-10-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
EP2448581B1 (en) 2009-06-29 2016-12-07 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
KR20130038224A (ko) * 2010-03-15 2013-04-17 가부시키가이샤 구라레 티에노피리딘 유도체 및 그 제조 방법, 그리고 그것을 사용한 유기 반도체 디바이스
JP5743418B2 (ja) * 2010-04-09 2015-07-01 Ｏａｔアグリオ株式会社 新規なピラゾール化合物、その製造方法及び有害生物防除剤
CN103260702B (zh) * 2010-10-28 2018-07-27 帕西拉制药有限公司 非甾体类抗炎药的缓释制剂
AU2011343712B2 (en) 2010-12-16 2015-09-17 Genentech, Inc. Tricyclic PI3k inhibitor compounds and methods of use
CA2821975A1 (en) 2010-12-17 2012-06-21 Shunqi Yan N-(4-(azetidine-1-carbonyl)phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase m2 pkm2 modulators
WO2012088314A1 (en) 2010-12-21 2012-06-28 Agios Pharmaceuticals, Inc. Bicyclic pkm2 activators
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
RU2013138835A (ru) * 2011-02-09 2015-03-20 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения в качестве ингибиторов pi3 киназы
US9181231B2 (en) 2011-05-03 2015-11-10 Agios Pharmaceuticals, Inc Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
JP6272754B2 (ja) 2011-05-03 2018-01-31 アジオス ファーマシューティカルズ， インコーポレイテッド ピルビン酸キナーゼ活性化剤の使用方法
US9446175B2 (en) 2011-06-03 2016-09-20 Yale University Compositions and methods for treating and preventing neointimal stenosis
CN102660253B (zh) * 2012-03-07 2014-05-21 泰山医学院 一种吡唑啉衍生物类Ni2+荧光探针及其应用
WO2014089364A1 (en) 2012-12-06 2014-06-12 Quanticel Pharmaceuticals, Inc Histone demethylase inhibitors
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
US20160137624A1 (en) * 2013-06-20 2016-05-19 Basf Se Process for preparing pyridylpyrazole compounds and derivatives thereof from pyridylhydrazine
RS64777B1 (sr) 2015-06-11 2023-11-30 Agios Pharmaceuticals Inc Postupci upotrebe aktivatora piruvat kinaze
ES3038189T3 (en) 2015-12-11 2025-10-10 Res Inst Nationwide Childrens Hospital Systems and methods for optimized patient specific tissue engineering vascular grafts
KR102434226B1 (ko) * 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
CA3038534A1 (en) * 2016-09-30 2018-04-05 Intercept Pharmaceuticals, Inc. Crystalline forms of a bile acid derivative
CN109983013A (zh) 2016-11-18 2019-07-05 帕西拉制药有限公司 美洛昔康锌复合物微粒多囊脂质体制剂及其制备方法
AU2021300281A1 (en) * 2020-06-30 2023-02-02 Dermira, Inc. RORγt inhibitors and topical uses thereof
CN116249692B (zh) * 2020-09-28 2024-08-23 四川科伦博泰生物医药股份有限公司 吡唑类化合物及其制备方法和用途
KR20240006582A (ko) * 2021-05-03 2024-01-15 티로나 바이오, 인코포레이티드 Alk-5 (tgf 베타 r1) 억제제로 폐 질환을 치료하기 위한 방법
IL316622A (en) * 2022-04-29 2024-12-01 Mannkind Corp Method and composition for treating lung diseases
WO2025090562A1 (en) * 2023-10-25 2025-05-01 Thirona Bio, Inc. Formulations of alk-5 kinase inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
UA80571C2 (en) * 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
SE0300120D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
AR048669A1 (es) * 2004-03-03 2006-05-17 Syngenta Ltd Derivados biciclicos de bisamida
US20080171755A1 (en) * 2004-08-31 2008-07-17 Wen-Cherng Lee Pyrimidinylpyrazoles as Tgf-Beta Inhibitors
US7511056B2 (en) * 2004-11-10 2009-03-31 Eli Lilly And Company TGF-β inhibitors
KR20090066297A (ko) * 2006-10-16 2009-06-23 화이자 프로덕츠 인크. 치료용 피라졸릴 티에노피리딘

Also Published As

Publication number Publication date
US8455512B2 (en) 2013-06-04
US9260450B2 (en) 2016-02-16
AU2007311560A1 (en) 2008-04-24
IL197750A0 (en) 2009-12-24
CA2666603A1 (en) 2008-04-24
EP2527345A1 (en) 2012-11-28
CL2007002916A1 (es) 2008-04-18
AU2007311560B2 (en) 2011-04-21
US9090625B2 (en) 2015-07-28
JP2010506895A (ja) 2010-03-04
US20080090861A1 (en) 2008-04-17
UY30641A1 (es) 2008-05-31
US20140031385A1 (en) 2014-01-30
ES2435430T3 (es) 2013-12-19
EP2074128A1 (en) 2009-07-01
TW200825094A (en) 2008-06-16
EP2527345B1 (en) 2015-12-16
MX2009003157A (es) 2009-04-03
AR063318A1 (es) 2009-01-21
US20150175624A1 (en) 2015-06-25
JP5443988B2 (ja) 2014-03-19
US7964612B2 (en) 2011-06-21
WO2008047198A1 (en) 2008-04-24
CA2666603C (en) 2013-08-06
US9938289B2 (en) 2018-04-10
US20110224251A1 (en) 2011-09-15
CN101528752A (zh) 2009-09-09
ES2559521T3 (es) 2016-02-12
KR20090066297A (ko) 2009-06-23
EP2074128B1 (en) 2013-08-14
US20160200735A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
NO20062704L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
NO20090025L (no) Pyrrolotriazinkinaseinhibitorer
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
NO20062691L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
NO20083207L (no) Inhibitorer av IAP
NO20062689L (no) Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer
NO20076357L (no) Azabicykliske heterocykler som cannabinoid reseptor modulatorer
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20070529L (no) Kinazolindionderivater som parp-inhibitorer
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
NO20082096L (no) Azaindol-2-karboksamidderivativer
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
NO20083717L (no) Pyrrolotriazin-anilin prodrugforbindelser anvendbare som kinaseinhibitorer
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
NO20070323L (no) Organiske forbindelser
NO20084129L (no) Pyridin(3,4-B)Pyrazinoner
TW200714604A (en) Substituted heterocycles and the uses thereof
NO20081844L (no) Terapeutiske forbindelser
NO20070445L (no) Pyrimidinderivater.
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
DK2173749T3 (da) 2-oxo-2-(2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl)-acetamidderivater og beslægtede forbindelser som antisvampemidler
NO20073765L (no) Forbindelser for behandling av flaviviridae

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application